Evidence map›Paper›PMID 40035953›Full record

ArticleJournal of racial and ethnic health disparities2026

Racial Disparities in Mortality Rates among Patients with Hepatic Steatosis, Non-Alcoholic Fatty Liver Disease, and Non-Alcoholic Steatohepatitis: Insights from NHANES III Data.

Shahrzad Bazargan-Hejazi, Cameron Hines, Myra Usmani, Chris Argueta, Deyu Pan, Arleen F Brown

Abstract read
In one paragraph

Article in Journal of racial and ethnic health disparities, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shahrzad Bazargan-HejaziDepartment of Psychiatry and Biobehavioral Sciences, College of Medicine, Charles R. Drew University of Medicine and Science and UCLA David Geffen School of Medicine, Los Angeles, CA, USA. Shahrzad.bazargan@alwmed.org.ORCID 0000-0001-8361-5198
Cameron HinesDepartment of Psychiatry and Biobehavioral Sciences, College of Medicine, Charles R. Drew University of Medicine and Science and UCLA David Geffen School of Medicine, Los Angeles, CA, USA.
Myra UsmaniUniversity of California, Riverside, College of Natural and Agricultural Sciences, Riverside, CA, 92507, USA.
Chris ArguetaCollege of Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, CA, USA.
Deyu PanCharles R. Drew University of Medicine and Science, Los Angeles, CA, USA.
Arleen F BrownUCLA Ronald Reagan Medical Center and Olive View Medical, Los Angeles, CA, USA.

Funding

Clinical and Translational Science Institute, University of California, Los Angeles UL1TR001881
6 · The paper itself

Abstract

backgroundInsufficient research has been done on NASH-related cirrhosis mortality and potential racial disparities in mortality rates.

objectiveThis study aims to analyze racial differences in mortality rates among patients with non-alcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), and non-alcoholic steatohepatitis (NASH), hypothesizing that hazard ratios for mortality among patients with NAFLD, NAFL, and NASH would be significantly different for Mexican American patients compared to other racial groups.

methodsData from NHANES III (1988-1994) representing the U.S. population were analyzed. Bivariate analysis and Cox proportional hazards models were employed to determine mortality rates and predictors across different racial/ethnic groups, adjusting for variables age, gender, smoking status (current, former, non-smoker), BMI (normal, overweight, obese), and a series of biomarkers.

resultsThe prevalence of liver diseases in the sample was: NAFLD (12.1%), NAFL (20.0%), and NASH (3.1%). Deceased patients with NASH had the highest weighted mortality rate (50.6%), followed by NAFLD (39.1%) and NAFL (35.5%). Compared to White patients, Black and Mexican American patients exhibited lower mortality rates for NAFLD. Mexican American patients also had lower mortality rates for NFAL and NASH. White patients showed higher hazard ratios (HR) for NAFLD and NAFL compared to Black and Mexican-American patients. However, for NASH, there were no significant differences in HR between racial/ethnic groups.

conclusionsDespite higher prevalence rates among Mexican American and Black patients, their mortality rates for NAFLD, NAFL, and NASH were comparable or lower than those for Whites. This highlights the need for further research to inform better management and treatment strategies.

Indexed as

Fatty LiverHealth Status DisparitiesNon-alcoholic Fatty Liver DiseaseAdultAgedBlack or African AmericanFemaleHumansMaleMexican AmericansMiddle AgedNutrition SurveysProportional Hazards ModelsUnited StatesWhiteWhite PeopleLiver diseaseMortalityNAFLNAFLDNASHRacial disparities

Identifiers

PMID40035953
PMCPMC12965913

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.